Lynparza
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
FDA Grants New Pancreatic Cancer Indication for Lynparza
Lynparza can now be used for the maintenance treatment of adult patients with deleterious or suspected deleterious ...
JANUARY 7, 2020
FDA Approves Lynparza for Certain Advanced Ovarian Cancer
Lynparza is indicated for patients with deleterious or suspected deleterious gBRCAm or sBRCAm advanced epithelial ...
DECEMBER 28, 2018
Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial
Maintenance therapy with olaparib can reduce the risk for ovarian cancer disease progression and related death by ...
NOVEMBER 27, 2018
Lynparza Approved to Treat BRCA-Mutated Metastatic Breast Cancer
The FDA expanded the approved use of olaparib (Lynparza, AstraZeneca) to include the treatment of patients with ...
JANUARY 14, 2018
Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer
Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in ...
JULY 12, 2017
